PRESS RELEASE published on 04/17/2024 at 07:15, 5 months 1 day ago Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera Spexis AG extends moratorium and receives payment for antibiotics program sale while reverting lonodelestat license from Santhera Spexis AG Moratorium Extension Antibiotics Program Sale Lonodelestat License Santhera
PRESS RELEASE published on 02/08/2024 at 07:15, 7 months 10 days ago Spexis announces closing of sale of preclinical antibiotics program to Basilea Spexis AG announces the closing of the sale of a preclinical antibiotics program to Basilea, which will pay up to CHF 2 million for the program. The program targets Gram-negative bacteria, including multidrug-resistant strains. The sale is part of Spexis' strategy to divest non-core programs and assets to focus on rare diseases and oncology Spexis AG Basilea Preclinical Antibiotics Program Gram-negative Bacteria Multidrug-resistant Strains
PRESS RELEASE published on 11/08/2023 at 07:15, 10 months 10 days ago Spexis to file an application for a debt-restructuring moratorium
PRESS RELEASE published on 11/01/2023 at 07:20, 10 months 17 days ago Spexis Announces Changes to the Executive Committee
PRESS RELEASE published on 10/06/2023 at 07:30, 11 months 12 days ago Spexis to host business update conference call on October 9, 2023
PRESS RELEASE published on 09/29/2023 at 07:25, 11 months 19 days ago Spexis provides business update and announces financial results for the first half of 2023
PRESS RELEASE published on 09/28/2023 at 07:30, 11 months 20 days ago Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
PRESS RELEASE published on 08/15/2023 at 07:25, 1 year 1 month ago Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
PRESS RELEASE published on 07/18/2023 at 12:26, 1 year 2 months ago Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 06/30/2023 at 07:15, 1 year 2 months ago Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
Published on 09/19/2024 at 03:20, 37 minutes ago How to Sell a Business Online Guide for Small Business Owners Released by the Business Brokers Directory
Published on 09/18/2024 at 23:10, 4 hours 47 minutes ago Ur-Energy Provides Operations, Construction and 2024 Guidance Updates
Published on 09/18/2024 at 23:00, 4 hours 57 minutes ago Garden State Gold & Coin Applauds Passage of Historic NJ Sales Tax Bill on Precious Metals
Published on 09/18/2024 at 21:15, 6 hours 42 minutes ago New to the Street Launches 24-Part Series with ARAX Holdings, Spotlighting Core Blockchain, CorePass, Lunaº Mesh, and Revolutionary Tech Solutions
Published on 09/18/2024 at 21:00, 6 hours 57 minutes ago Falcon Commences Drilling At Its Great Burnt Copper Project, NL
Published on 09/18/2024 at 19:11, 8 hours 45 minutes ago EQS-Adhoc: alstria office REIT-AG: squeeze-out demand regarding the shares of minority shareholders, amendment to investment agreement, loss of REIT-status at year-end 2024
Published on 09/18/2024 at 18:45, 9 hours 11 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/18/2024 at 18:31, 9 hours 25 minutes ago EQS-Adhoc: Vonovia SE: Initiation of the process to conclude a domination and profit and loss transfer agreement between Vonovia SE and Deutsche Wohnen SE
Published on 09/18/2024 at 18:13, 9 hours 43 minutes ago BILENDI: Creating discussion guides for market research is now possible with AI, thanks to BARI and Bilendi Discuss
Published on 09/18/2024 at 17:21, 10 hours 35 minutes ago EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Published on 09/18/2024 at 18:45, 9 hours 11 minutes ago Augmentation de capital consécutive à l'attribution gratuite d'actions aux salariés du groupe EuropaCorp
Published on 09/18/2024 at 18:45, 9 hours 11 minutes ago Capital increase following the allocation of free shares to EuropaCorp employees
Published on 09/18/2024 at 17:40, 10 hours 17 minutes ago Groupe CRIT : Modalités de mise à disposition du Rapport Financier semestriel 2024.